SCHEMBL451645

SCHEMBL451645

COc1ccc(-n2c(C(C)N(C)S(=O)(=O)c3ccc(C(C)(C)C)cc3)nc3cccc(C)c3c2=O)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR3 P49682 2/20 0.38
HRH3 Q9Y5N1 2/20 0.37
KCNH2 Q12809 1/20 0.37
PIK3CD O00329 2/20 0.37
HSD11B1 P28845 1/20 0.37
ALDH1A1 P00352 4/20 0.36
PDE10A Q9Y233 1/20 0.36
PTGER2 P43116 2/20 0.36
GPR139 Q6DWJ6 1/20 0.35
MMP2 P08253 1/20 0.35
MMP3 P08254 1/20 0.35
MMP9 P14780 1/20 0.35
MMP13 P45452 1/20 0.35
NPBWR1 P48145 1/20 0.35
MCHR1 Q99705 1/20 0.35
PRSS1 P07477 1/20 0.35
C1R P00736 1/20 0.35
KEAP1 Q14145 1/20 0.34
RAB9A P51151 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL452305 0.94 CXCR3 (0.41) CXCR3HRH3KCNH2PIK3CDALDH1A1
SCHEMBL453148 0.92 CXCR3 (0.44) CXCR3HRH3KCNH2PIK3CDALDH1A1
SCHEMBL452097 0.92 HRH3 (0.39) CXCR3HRH3KCNH2HSD11B1ALDH1A1
SCHEMBL450632 0.91 ALDH1A1 (0.42) CXCR3HRH3KCNH2PIK3CDALDH1A1
SCHEMBL448724 0.90 NPBWR1 (0.40) CXCR3HRH3KCNH2PIK3CDALDH1A1
SCHEMBL452784 0.89 ALDH1A1 (0.44) CXCR3HRH3KCNH2PIK3CDALDH1A1
SCHEMBL451205 0.87 CXCR3 (0.50) CXCR3ALDH1A1PDE10APRSS1C1R
SCHEMBL451913 0.86 KEAP1 (0.39) CXCR3HRH3KCNH2HSD11B1ALDH1A1
SCHEMBL452063 0.85 CXCR3 (0.44) CXCR3HRH3KCNH2PIK3CDALDH1A1
SCHEMBL449419 0.85 ALDH1A1 (0.50) CXCR3ALDH1A1PDE10APRSS1C1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748440-B2 Quinazolinone modulators of nuclear receptors EXELIXIS, INC. (US) 2014-06-10 US claimed
US-20120064025-A1 Quinazolinone Modulators Of Nuclear Receptors EXELIXIS, INC. (US) 2012-03-15 US claimed
EP-1521746-B1 QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS X CEPTOR THERAPEUTICS INC (US) 2011-04-27 EP claimed
US-20080070864-A1 Quinazolinone Modulators Of Nuclear Receptors X-CEPTOR THERAPEUTICS, INC. (US) 2008-03-20 US claimed
US-8748440-B2 Quinazolinone modulators of nuclear receptors EXELIXIS, INC. (US) 2014-06-10 US disclosed
US-20120064025-A1 Quinazolinone Modulators Of Nuclear Receptors EXELIXIS, INC. (US) 2012-03-15 US disclosed
EP-1521746-B1 QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS X CEPTOR THERAPEUTICS INC (US) 2011-04-27 EP disclosed
US-20080070864-A1 Quinazolinone Modulators Of Nuclear Receptors X-CEPTOR THERAPEUTICS, INC. (US) 2008-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120064025-A1 Quinazolinone Modulators Of Nuclear Receptors NR1H4, NR1H2, NR1H3 CXCR3 741/4885HRH3 886/4885KCNH2 4581/4885
US-20080070864-A1 Quinazolinone Modulators Of Nuclear Receptors NR1H4, NR1H2, NR1H3 CXCR3 741/4885HRH3 886/4885KCNH2 4581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.